Funding for this research was provided by:
Janssen Research and Development (NA)
Received: 5 April 2019
Accepted: 19 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: The use of IBM MarketScan® Commercial Database was reviewed by the New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subjects research.
: Not applicable.
: All authors are employees of Janssen Pharmaceuticals, LLC, a Johnson & Johnson company, and shareholders in Johnson & Johnson. Janssen markets a fluoroquinolone in some countries.